Cwm, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Cwm, LLC

$20.6 Billion
Q1 2024

A detailed history of Cwm, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 99,343 shares of ARWR stock, worth $2.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

99,343

Previous 103,014 3.56%

Holding current value

$2.49 Million

Previous $3.15 Million 9.87%

% of portfolio

0.01%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 05, 2024	SELL	$27.21 - $39.48 $99,887 - $144,931	-3,671 Reduced 3.56%	99,343 $2.84 Million
Q4 2023 Feb 01, 2024	SELL	$21.2 - $31.03 $120,903 - $176,964	-5,703 Reduced 5.25%	103,014 $3.15 Million
Q3 2023 Oct 11, 2023	SELL	$26.2 - $36.08 $111,481 - $153,520	-4,255 Reduced 3.77%	108,717 $2.92 Million
Q2 2023 Aug 03, 2023	BUY	$25.16 - $41.38 $668,627 - $1.1 Million	26,575 Added 30.76%	112,972 $4.03 Million
Q1 2023 Apr 28, 2023	SELL	$23.68 - $38.51 $95,288 - $154,964	-4,024 Reduced 4.45%	86,397 $2.19 Million

Q4 2022 Feb 01, 2023	SELL	$28.0 - $40.56 $497,252 - $720,305	-17,759 Reduced 16.42%	90,421 $3.67 Million
Q3 2022 Oct 27, 2022	SELL	$29.63 - $48.31 $122,668 - $200,003	-4,140 Reduced 3.69%	108,180 $3.58 Million
Q2 2022 Jul 28, 2022	SELL	$27.79 - $50.61 $452,921 - $824,841	-16,298 Reduced 12.67%	112,320 $3.96 Million
Q1 2022 Apr 21, 2022	SELL	$39.62 - $69.97 $805,236 - $1.42 Million	-20,324 Reduced 13.65%	128,618 $5.92 Million
Q4 2021 Jan 31, 2022	BUY	$58.09 - $82.51 $3.88 Million - $5.51 Million	66,746 Added 81.2%	148,942 $9.88 Million
Q1 2021 Sep 15, 2021	BUY	$61.35 - $90.47 $1.32 Million - $1.95 Million	21,508 Added 35.44%	82,196 $6.81 Million
Q1 2021 Apr 27, 2021	SELL	$61.35 - $90.47 $1.32 Million - $1.95 Million	-21,508 Reduced 26.17%	60,688 $4.02 Million
Q4 2020 Sep 15, 2021	BUY	$43.82 - $85.37 $940,815 - $1.83 Million	21,470 Added 35.36%	82,196 $6.81 Million
Q4 2020 Jan 27, 2021	SELL	$43.82 - $85.37 $940,815 - $1.83 Million	-21,470 Reduced 26.12%	60,726 $4.66 Million
Q3 2020 Sep 15, 2021	BUY	$33.21 - $51.27 $2.71 Million - $4.18 Million	81,586 Added 13374.75%	82,196 $6.81 Million
Q3 2020 Oct 19, 2020	SELL	$33.21 - $51.27 $2.71 Million - $4.18 Million	-81,586 Reduced 99.26%	610 $26,000
Q2 2020 Sep 15, 2021	BUY	$26.12 - $43.27 $2.13 Million - $3.53 Million	81,586 Added 13374.75%	82,196 $6.81 Million
Q2 2020 Jul 22, 2020	SELL	$26.12 - $43.27 $2.13 Million - $3.53 Million	-81,586 Reduced 99.26%	610 $26,000
Q1 2020 Sep 15, 2021	BUY	$20.56 - $63.12 $1.68 Million - $5.16 Million	81,786 Added 19947.8%	82,196 $6.81 Million
Q1 2020 Apr 28, 2020	SELL	$20.56 - $63.12 $1.68 Million - $5.16 Million	-81,786 Reduced 99.5%	410 $12,000
Q4 2019 Sep 14, 2021	BUY	$28.14 - $73.01 $2.31 Million - $6 Million	82,136 Added 136893.33%	82,196 $6.81 Million
Q4 2019 Jan 27, 2020	SELL	$28.14 - $73.01 $2.31 Million - $6 Million	-82,136 Reduced 99.93%	60 $4,000
Q3 2019 Sep 14, 2021	BUY	$26.26 - $34.86 $2.16 Million - $2.86 Million	82,136 Added 136893.33%	82,196 $6.81 Million
Q3 2019 Oct 22, 2019	SELL	$26.26 - $34.86 $2.16 Million - $2.86 Million	-82,136 Reduced 99.93%	60 $2,000
Q2 2019 Sep 14, 2021	BUY	$17.43 - $28.82 $1.43 Million - $2.37 Million	82,136 Added 136893.33%	82,196 $6.81 Million
Q2 2019 Jul 31, 2019	SELL	$17.43 - $28.82 $1.43 Million - $2.37 Million	-82,136 Reduced 99.93%	60 $2,000
Q1 2019 Sep 02, 2021	BUY	$12.05 - $20.18 $989,509 - $1.66 Million	82,117 Added 103945.57%	82,196 $0
Q1 2019 Apr 22, 2019	BUY	$12.05 - $20.18 $228 - $383	19 Added 31.67%	79 $1,000
Q3 2017 Oct 16, 2017	BUY	$1.69 - $4.33 $101 - $259	60	60 $0

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.65B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account